Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug
- PMID: 19680025
- DOI: 10.1097/MAJ.0b013e3181a3c2c9
Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug
Abstract
Torsade de pointes (TdP) or "twisting of the points" represents polymorphic ventricular tachycardia in the setting of prolonged QT interval and is characterized by QRS complexes that change in morphology and amplitude. We report a rare case of TdP, associated with QT interval prolongation, caused by intravenous moxifloxacin given for pneumonia in a 71-year-old African American man. Electrocardiogram initially revealed QT interval prolongation that led to torsades de pointes. These changes reverted to normal when moxifloxacin was held. Although the risk for quinolone-associated TdP seems to be low, caution is still warranted when given someone with high risk of QT prolongation.
Similar articles
-
Moxifloxacin-induced torsades de pointes.Cardiol J. 2008;15(1):71-3. Cardiol J. 2008. PMID: 18651388
-
Arrhythmias associated with fluoroquinolone therapy.Int J Antimicrob Agents. 2007 Apr;29(4):374-9. doi: 10.1016/j.ijantimicag.2006.11.011. Epub 2007 Jan 22. Int J Antimicrob Agents. 2007. PMID: 17241772 Review.
-
Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event.Can J Cardiol. 2007 Sep;23(11):907-8. doi: 10.1016/s0828-282x(07)70850-4. Can J Cardiol. 2007. PMID: 17876386 Free PMC article.
-
Moxifloxacin and torsade de pointes.Ann Pharmacother. 2007 Feb;41(2):336-40. doi: 10.1345/aph.1H474. Epub 2007 Feb 6. Ann Pharmacother. 2007. PMID: 17284508
-
QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.Cardiology. 2011;120(2):103-10. doi: 10.1159/000334441. Epub 2011 Dec 13. Cardiology. 2011. PMID: 22156660 Review.
Cited by
-
Fluoroquinolones and Cardiovascular Risk: A Systematic Review, Meta-analysis and Network Meta-analysis.Drug Saf. 2019 Apr;42(4):529-538. doi: 10.1007/s40264-018-0751-2. Drug Saf. 2019. PMID: 30368737
-
Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin.AAPS J. 2018 Mar 14;20(3):47. doi: 10.1208/s12248-018-0199-4. AAPS J. 2018. PMID: 29541956
-
Thorough QT Studies: Questions and Quandaries.Drug Saf. 2010 Jan 1;33(1):1-14. doi: 10.2165/11319160-000000000-00000. Drug Saf. 2010. PMID: 20000862 Review.
-
Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.PLoS One. 2016 Dec 30;11(12):e0163619. doi: 10.1371/journal.pone.0163619. eCollection 2016. PLoS One. 2016. PMID: 28036334 Free PMC article. Clinical Trial.
-
The association between QT interval changes and the treatment protocols of COVID-19 patients.North Clin Istanb. 2022 Jul 7;9(3):199-206. doi: 10.14744/nci.2022.86836. eCollection 2022. North Clin Istanb. 2022. PMID: 36199861 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources